Padcev, the first targeted treatment for metastatic urothelial cancer, can now be prescribed at tertiary hospitals in Korea.

According to industry sources, Astellas Pharma Korea’s Padcev (enfortumab vedotin) has passed the review of drug committees (DCs) at all of the ‘Big 5’ tertiary hospitals in Korea - the Samsung Medical Center, Seoul, Asan Medical Center, Seoul St.Mary’s Hospital, Sinchon Severance Hospital, with the Seoul National University Hospital being the last.

Padcev is a first-in-class antibody-drug conjugate (ADC) that is directed against Nectin-4. It is recommended as Category 1 in the National Comprehensive Cancer Network (NCCN) guidelines. It is a new treatment opti